1.Survey of Wild Mammal Hosts of Cutaneous Leishmaniasis Parasites in Panamá and Costa Rica
Kadir González ; José E. Calzada ; Azael Saldaña ; Chystrie A. Rigg ; Gilbert Alvarado ; Bernal Rodríguez-Herrera ; Uriel D. Kitron ; Gregory H. Adler ; Nicole L. Gottdenker ; Luis Fernando Chaves ; Mario Baldi
Tropical Medicine and Health 2015;43(1):75-78
The eco-epidemiology of American cutaneous leishmaniasis (ACL) is driven by animal reservoir species that are a source of infection for sand flies that serve as vectors infecting humans with Leishmania spp parasites. The emergence and re-emergence of this disease across Latin America calls for further studies to identify reservoir species associated with enzootic transmission. Here, we present results from a survey of 52 individuals from 13 wild mammal species at endemic sites in Costa Rica and Panama where ACL mammal hosts have not been previously studied. For Leishmania spp. diagnostics we employed a novel PCR technique using blood samples collected on filter paper. We only found Leishmania spp parasites in one host, the two-toed sloth, Choloepus hoffmanni. Our findings add further support to the role of two-toed sloths as an important ACL reservoir in Central America.
2.Survey of Wild Mammal Hosts of Cutaneous Leishmaniasis Parasites in Panamá and Costa Rica
Kadir González ; José E. Calzada ; Azael Saldaña ; Chystrie A. Rigg ; Gilbert Alvarado ; Bernal Rodríguez-Herrera ; Uriel D. Kitron ; Gregory H. Adler ; Nicole L. Gottdenker ; Luis Fernando Chaves ; Mario Baldi
Tropical Medicine and Health 2014;():-
The eco-epidemiology of American Cutaneous Leishmaniasis (ACL) is drivenby animal reservoir species that are a source of infection for sand flies thatserve as vectors infecting humans with Leishmania spp parasites. The emergence and re-emergence of this disease across LatinAmerica calls for further studies to identify reservoir species associated withenzootic transmission. Here, we present results from a survey of 52 individualsfrom 13 wild mammal species at endemic sites in Costa Rica and Panama where ACLMammal hosts have not been previously studied. For Leishmania spp. diagnostics we employed a novel PCR technique usingblood samples collected on filter paper. We only found Leishmania spp parasites in one host, the two toed sloth, Choloepus hoffmanni. Our findings addfurther support to the major role of two toed sloths as an ACL reservoir inCentral America.
3.Fluorescence Guided Surgery with 5-Aminolevulinic Acid for Resection of Spinal Cord Ependymomas
Rafael García MORENO ; Luis Miguel Bernal GARCÍA ; Hyaissa Ippolito BASTIDAS ; Carlos Andrés Mondragón TIRADO ; Aurora Moreno FLORES ; Juan Pablo Sosa CABEZAS ; José Manuel Cabezudo ARTERO
Asian Spine Journal 2019;13(1):119-125
STUDY DESIGN: A retrospective study. PURPOSE: We report our experience with 5-aminolevulinic acid (5-ALA)–assisted resection of spinal cord ependymomas in adults. OVERVIEW OF LITERATURE: Ependymoma is the most frequent primary spinal cord tumor in adults. Surgery is the treatment of choice in most cases. However, while complete resection is achieved in approximately 80% of cases, clinical improvement is achieved in 15% only. Five-ALA fluorescence–guided surgery seems to be useful for this tumor type. METHODS: We studied 14 patients undergoing 5-ALA fluorescence-guided surgery for spinal cord ependymomas in our service. The modified McCormick classification was used to determine clinical status and the degree of resection was assessed with magnetic resonance imaging. RESULTS: Of the 14 patients, the tumor showed an intense emission of fluorescence in 12 and the fluorescence was weak and nonuniform in two. Complete resection was achieved in 11 cases. According to the McCormick classification, 10 patients improved, two remained the same, and two deteriorated. CONCLUSIONS: Our results confirm that 5-ALA fluorescence-guided resection is useful in spinal cord ependymoma resection. Although the rate of complete resections is similar to that in published series without 5-ALA, clinical results are better when using 5-ALA with a lower percentage of clinical deterioration.
Adult
;
Aminolevulinic Acid
;
Classification
;
Ependymoma
;
Fluorescence
;
Humans
;
Magnetic Resonance Imaging
;
Retrospective Studies
;
Spinal Cord Neoplasms
;
Spinal Cord
4.Characteristics and in-hospital mortality of elderly patients with heart failure in Spanish hospitals.
Alberto ESTEBAN-FERNÁNDEZ ; Manuel ANGUITA-SÁNCHEZ ; Juan Luis BONILLA-PALOMAS ; María ANGUITA-GÁMEZ ; María GARCÍA ; José Luis BERNAL ; Náyade Del PRADO ; Cristina FERNÁNDEZ-PÉREZ ; Julián PÉREZ-VILLACASTIN ; Juan José GÓMEZ-DOBLAS ; Francisco Javier ELOLA
Journal of Geriatric Cardiology 2023;20(4):247-255
BACKGROUND:
The prevalence of heart failure (HF) increases with age, and it is one of the leading causes of hospitalization and death in older patients. However, there are little data on in-hospital mortality in patients with HF ≥ 75 years in Spain.
METHODS:
A retrospective analysis of the Spanish Minimum Basic Data Set was performed, including all HF episodes discharged from public hospitals in Spain between 2016 and 2019. Coding was performed using the International Classification of Diseases, 10th Revision. Patients ≥ 75 years with HF as the principal diagnosis were selected. We calculated: (1) the crude in-hospital mortality rate and its distribution according to age and sex; (2) the risk-standardized in-hospital mortality ratio; and (3) the association between in-hospital mortality and the availability of an intensive cardiac care unit (ICCU) in the hospital.
RESULTS:
We included 354,792 HF episodes of patients over 75 years. The mean age was 85.2 ± 5.5 years, and 59.2% of patients were women. The most frequent comorbidities were renal failure (46.1%), diabetes mellitus (35.5%), valvular disease (33.9%), cardiorespiratory failure (29.8%), and hypertension (26.9%). In-hospital mortality was 12.7%, and increased with age [odds ratio (OR) = 1.07, 95% CI: 1.07-1.07, P < 0.001] and was lower in women (OR = 0.96, 95% CI: 0.92-0.97, P < 0.001). The main predictors of mortality were the presence of cardiogenic shock (OR = 19.5, 95% CI: 16.8-22.7, P < 0.001), stroke (OR = 3.5, 95% CI: 3.0-4.0, P < 0.001) and advanced cancer (OR = 2.6, 95% CI: 2.5-2.8, P < 0.001). In hospitals with ICCU, the in-hospital risk-adjusted mortality tended to be lower (OR = 0.85, 95% CI: 0.72-1.00, P = 0.053).
CONCLUSIONS
In-hospital mortality in patients with HF ≥ 75 years between 2016 and 2019 was 12.7%, higher in males and elderly patients. The main predictors of mortality were cardiogenic shock, stroke, and advanced cancer. There was a trend toward lower mortality in centers with an ICCU.